Drug Type Small molecule drug |
Synonyms Omipalisib (USAN/INN), GSK-212, GSK-2126458 + [1] |
Target |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), mTORC1 inhibitors(Mammalian target of Rapamycin (mTORC1) inhibitors), mTORC2 inhibitors(mTOR Complex 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC25H17F2N5O3S |
InChIKeyCGBJSGAELGCMKE-UHFFFAOYSA-N |
CAS Registry1086062-66-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Pulmonary Fibrosis | Phase 1 | GB | 08 Mar 2013 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 03 Dec 2010 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 03 Dec 2010 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IT | 03 Dec 2010 | |
Lymphoma | Phase 1 | US | 31 Aug 2009 | |
Lymphoma | Phase 1 | NL | 31 Aug 2009 | |
Solid tumor | Phase 1 | US | 31 Aug 2009 | |
Solid tumor | Phase 1 | NL | 31 Aug 2009 |
Phase 1 | 69 | foxmyticxi(dmpubzcuqn) = qnczilvtkh spemycdxdm (oqbajhccia ) View more | Negative | 01 Dec 2016 | |||
Phase 1 | 78 | fdkbghbkok(ntrhjfcqdo) = yvyusauqto exmnwimxym (ziuvwnasiz ) View more | - | 20 May 2011 |